Read full article here.
Lincoln Pharmaceuticals Limited has reported Consolidated financial results for the period ended June 30, 2023.
Financial Results (Q1 FY2024) – QoQ Comparison
The company has reported total income of Rs. 143.3103 crores during the period ended June 30, 2023 as compared to Rs. 116.3588 crores during the period ended March 31, 2023.
The company has posted net profit / (loss) of Rs. 19.0134 crores for the period ended June 30, 2023 as against net profit / (loss) of Rs. 12.5617 crores for the period ended March 31, 2023.
The company has reported EPS of Rs. 9.49 for the period ended June 30, 2023 as compared to Rs. 6.27 for the period ended March 31, 2023.
Financials | Q1 FY2024 | Q4 FY2023 | % Change |
Total Income | ₹ 143.3103 crs | ₹116.3588 crs | 23.16% |
Net Profit | ₹19.0134 crs | ₹12.5617 crs | 51.36% |
EPS | ₹9.49 | ₹6.27 | 51.36% |
Financial Results (Q1 FY2024) – YoY Comparison
The company has reported total income of Rs. 143.3103 crores during the period ended June 30, 2023 as compared to Rs.129.9656 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs.19.0134 crores for the period ended June 30, 2023 as against net profit / (loss) of Rs.15.0116 crores for the period ended June 30, 2022.
The company has reported EPS of Rs.9.49 for the period ended June 30, 2023 as compared to Rs.7.49 for the period ended June 30, 2022.
Financials | Q1 FY2024 | Q1 FY2023 | % Change |
Total Income | ₹ 143.3103 crs | ₹129.9656 crs | 10.27% |
Net Profit | ₹19.0134 crs | ₹15.0116 crs | 26.66% |
EPS | ₹9.49 | ₹7.49 | 26.70% |
Shares of Lincoln Pharmaceuticals Limited was last trading in BSE at Rs. 489.00 as compared to the previous close of Rs. 451.55. The total number of shares traded during the day was 86467 in over 4947 trades.
The stock hit an intraday high of Rs. 495.90 and intraday low of 450.45. The net turnover during the day was Rs. 41586568.00.